2. Search Result
Search Result
Isoforms Recommended: CDC
Results for "

Cdc7

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Recombinant Proteins

3

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13461
    PHA-767491
    4 Publications Verification

    CAY10572

    		 CDK Cancer
    PHA-767491 is a dual Cdc7/Cdk9 inhibitor, with IC50s of 10 nM and 34 nM, respectively.
    PHA-767491
  • HY-100888
    Simurosertib
    Maximum Cited Publications
    11 Publications Verification

    TAK-931

    		 CDK Cancer
    Simurosertib (TAK-931) is an orally active, selective and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor, with an IC50 of <0.3 nM. Simurosertib has anti-cancer activity .
    Simurosertib
  • HY-15260
    XL413
    5+ Cited Publications

    BMS-863233

    		 CDK Cancer
    XL413 is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC50 of 3.4 nM, and also shows potent effect with IC50s of 215, 42 nM on CK2, PIM1, respectively, and an EC50 of 118 nM on pMCM.
    XL413
  • HY-W011109
    CKI-7
    1 Publications Verification

    		 Casein Kinase CDK SGK Ribosomal S6 Kinase (RSK) Cancer
    CKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 has a much weaker effect on casein kinase II and other protein kinases .
    CKI-7
  • HY-148065
    FMF-06-098-1

    		PROTACs Wee1 CDK AAK1 ULK MELK Itk IRAK Ephrin Receptor FGFR MAP4K p38 MAPK Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    FMF-06-098-1 is a multi-target kinase PROTAC degrader. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .
    FMF-06-098-1
  • HY-13461A
    PHA-767491 hydrochloride
    4 Publications Verification

    CAY-10572 hydrochloride

    		 CDK Apoptosis Cancer
    PHA-767491 hydrochloride is a dual Cdc7/Cdk9 inhibitor, with IC50s of 10 nM and 34 nM, respectively.
    PHA-767491 hydrochloride
  • HY-100023
    LY3177833

    		CDK Cancer
    LY3177833 (Example 4) is an orally active CDC7 and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducer .
    LY3177833
  • HY-15260A
    XL413 monohydrochloride
    5+ Cited Publications

    BMS-863233 monohydrochloride

    		 CDK Cancer
    XL413 (BMS-863233) hydrochloride is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC50 of 3.4 nM, and also shows potent effect with IC50s of 215, 42 nM on CK2, PIM1, respectively, and an EC50 of 118 nM on pMCM.
    XL413 monohydrochloride
  • HY-133028
    CKI-7 free base
    1 Publications Verification

    		 Casein Kinase CDK SGK Ribosomal S6 Kinase (RSK) Cancer
    CKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 free base is a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 free base has a much weaker effect on casein kinase II and other protein kinases .
    CKI-7 free base
  • HY-101523
    Cdc7-IN-1
    1 Publications Verification

    		 CDK Cancer
    Cdc7-IN-1 (Compound 13) is a highly potent, selective and ATP competitive inhibitor of Cdc7 kinase, with an IC50 value of 0.6 nM at 1 mM ATP and with slow off-rate characteristics. Cdc7-IN-1 potently inhibits Cdc7 activity in cancer cells, and effectively induces cell death .
    Cdc7-IN-1
  • HY-100888A
    (R)-Simurosertib

    (R)-TAK-931

    		 CDK Others
    (R)-Simurosertib ((R)-TAK-931) is the (R)-enantiomer of Simurosertib. Simurosertib (TAK-931) is an orally active, selective and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor, with an IC50 of <0.3 nM .
    (R)-Simurosertib
  • HY-RS02309
    CDC7 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) CDK Others

    CDC7 Human Pre-designed siRNA Set A contains three designed siRNAs for CDC7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CDC7 Human Pre-designed siRNA Set A
    CDC7 Human Pre-designed siRNA Set A
  • HY-RS23178
    Cdc7 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Cdc7 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdc7 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdc7 Rat Pre-designed siRNA Set A
    Cdc7 Rat Pre-designed siRNA Set A
  • HY-RS16741
    Cdc7 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Cdc7 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdc7 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdc7 Mouse Pre-designed siRNA Set A
    Cdc7 Mouse Pre-designed siRNA Set A
  • HY-143433
    Cdc7-IN-19

    		CDK Cancer
    Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC50 of 1.49 nM .
    Cdc7-IN-19
  • HY-130519
    Cdc7-IN-7

    		CDK Cancer
    Cdc7-IN-7 (compound I-E) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-E. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle .
    Cdc7-IN-7
  • HY-100023A
    LY3177833 monhydrate

    		CDK Cancer
    LY3177833 (Example 4) monhydrate is an orally active CDC7 and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively. LY3177833 monhydrate is a senescence inducer .
    LY3177833 monhydrate
  • HY-15260C
    XL413 hydrochloride

    BMS-863233 hydrochloride

    		 CDK Cancer
    XL413 (BMS-863233) hydrochloride is an orally active and selective CDC7 inhibitor (IC50=3.4 nM). XL413 hydrochloride has favorable pharmacokinetic profiles and significantly inhibits tumor growth in rodent models. XL413 hydrochloride can be used in cancer research .
    XL413 hydrochloride
  • HY-143431
    Cdc7-IN-17

    		CDK Cancer
    Cdc7-IN-17 is a potent CDC7 inhibitor with an IC50 of <10 μM, extracted from patent WO2018217439A1. Cdc7-IN-17 can be used for cancer research .
    Cdc7-IN-17
  • HY-163374
    Cdc7-IN-20

    		CDK Cancer
    Cdc7-IN-20 (EP-05) is an orally effective and selective Cdc7 inhibitor with IC50 and Ki values of 0.93 and 0.11 nM, respectively. Cdc7-IN-20 has antitumor activity .
    Cdc7-IN-20
  • HY-143377
    Cdc7-IN-8

    		CDK Cancer
    Cdc7-IN-8 is a potent inhibitor of Cdc7. Cdc7 is a serine/threonine kinase which activates MCM promotion by phosphorylating the microchromosome maintenance protein (MCM protein), an important element of the DNA replication initiator. Cdc7-IN-8 has the potential for the research of cancer diseases (extracted from patent WO2021032170A1, compound 1-1/1-2) .
    Cdc7-IN-8
  • HY-143432A
    (S)-Cdc7-IN-18

    		CDK Cancer
    (S)-Cdc7-IN-18 is a potent inhibitor of CDC7. Overexpression of huCdc7 promotes overactivation of MCM2, an important marker of tumor cells, and thus promotes aberrant proliferation of tumor cells. (S)-Cdc7-IN-18 has the potential for the research of cancer diseases (extracted from patent WO2020239107A1, compound 1-1) .
    (S)-Cdc7-IN-18
  • HY-143429
    Cdc7-IN-15

    		CDK Cancer
    Cdc7-IN-15 (Example 108) is a cdc7 kinase inhibitor. Cdc7-IN-15 can be used for cancer research .
    Cdc7-IN-15
  • HY-143389
    Cdc7-IN-14

    		CDK Cancer
    Cdc7-IN-14 (compound 82) is a potent CDC7 inhibitor with an IC50 of <1 nM. Cdc7-IN-14 has the potential for the research of cancer .
    Cdc7-IN-14
  • HY-143387
    Cdc7-IN-13

    		CDK Cancer
    Cdc7-IN-13 (compound 84) is a potent CDC7 inhibitor with an IC50 of <1 nM. Cdc7-IN-13 has the potential for the research of cancer .
    Cdc7-IN-13
  • HY-143385
    Cdc7-IN-12

    		CDK Cancer
    Cdc7-IN-12 (compound 1) is a potent CDC7 inhibitor with an IC50 of <1 nM. Cdc7-IN-12 shows antiproliferative activities with IC50 of 100-1000 nM in COLO205 cells. Cdc7-IN-12 has the potential for the research of cancer .
    Cdc7-IN-12
  • HY-143432
    Cdc7-IN-18

    		CDK Cancer
    Cdc7-IN-18 (compound 1-2) is a potent CDC7 inhibitor with an IC50 of 1.29 nM for Cdc7/DBF4 enzyme. Cdc7-IN-18 shows antiproliferative activities with IC50 of 53.62 nM in COLO205 cells .
    Cdc7-IN-18
  • HY-117677
    Cdc7-IN-21

    		CDK Cancer
    Cdc7-IN-21 (compound 10c) is a potent and selective Cdc7 inhibitor with an IC50 of 0.07 nM. Cdc7-IN-21 can be used to study cancer .
    Cdc7-IN-21
  • HY-143380
    Cdc7-IN-9

    		CDK Cancer
    Cdc7-IN-9 is a potent Cdc7 inhibitor and can be used for cancer research .
    Cdc7-IN-9
  • HY-130515
    Cdc7-IN-3

    		CDK Cancer
    Cdc7-IN-3 (compound I-A) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle .
    Cdc7-IN-3
  • HY-130517
    Cdc7-IN-5

    		CDK Cancer
    Cdc7-IN-5 (compound I-B) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle .
    Cdc7-IN-5
  • HY-130516
    Cdc7-IN-4

    		CDK Cancer
    Cdc7-IN-4 (compound I-C) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-C. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle .
    Cdc7-IN-4
  • HY-E70650
    CDC7/DBF4 Recombinant Human Active Protein Kinase

    		CDK Cancer
    CDC7/DBF4 Recombinant Human Active Protein Kinaseis a protein kinase that is required for the initiation of DNA replication in eukaryotes .
    CDC7/DBF4 Recombinant Human Active Protein Kinase
  • HY-162007
    PYRA-2

    		CDK Cancer
    PYRA-2 is a CDC7 kinase inhibitor with potential for cancer research .
    PYRA-2
  • HY-101523R
    Cdc7-IN-1 (Standard)

    		CDK Reference Standards Cancer
    Cdc7-IN-1 (Standard) is the analytical standard of Cdc7-IN-1 (HY-101523). This product is intended for research and analytical applications. Cdc7-IN-1 (Compound 13) is a highly potent, selective and ATP competitive inhibitor of Cdc7 kinase, with an IC50 value of 0.6 nM at 1 mM ATP and with slow off-rate characteristics. Cdc7-IN-1 potently inhibits Cdc7 activity in cancer cells, and effectively induces cell death .
    Cdc7-IN-1 (Standard)
  • HY-143430
    (S)-LY3177833

    		CDK Cancer
    (S)-LY3177833 ((S)-Example 2) is an orally active CDC7 kinase inhibitor. (S)-LY3177833 shows broad in vitro anticancer activity .
    (S)-LY3177833
  • HY-143430A
    (S)-LY3177833 hydrate

    		CDK Cancer
    (S)-LY3177833 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor. (S)-LY3177833 hydrate shows broad in vitro anticancer activity .
    (S)-LY3177833 hydrate
  • HY-100888R
    Simurosertib (Standard)

    TAK-931 (Standard)

    		 CDK Reference Standards Cancer
    Simurosertib (Standard) is the analytical standard of Simurosertib (HY-100888). This product is intended for research and analytical applications. Simurosertib (TAK-931) is an orally active, selective and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor, with an IC50 of <0.3 nM. Simurosertib has anti-cancer activity .
    Simurosertib (Standard)
  • HY-100888AR
    (R)-Simurosertib (Standard)

    		CDK Reference Standards Others
    (R)-Simurosertib (Standard) is the analytical standard of (R)-Simurosertib (HY-100888A). This product is intended for research and analytical applications. (R)-Simurosertib ((R)-TAK-931) is the (R)-enantiomer of Simurosertib. Simurosertib (TAK-931) is an orally active, selective and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor, with an IC50 of <0.3 nM .
    (R)-Simurosertib (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: